Acquisition Details
- Target Company: IQGenX Pharma Private Limited, founded in October 2016
- Stake Acquired: 76% majority stake
- Consideration: INR 91.2 million
- Business of Target: Custom research organization operating in formulation development of oral solids, sterile injectable and ophthalmic solutions for US, EU, Latin America, Middle East and other regulated markets
Strategic Rationale
- Enables Alivus to leverage its core API portfolio selectively into advanced formulation development
- Creates integrated end-to-end platform delivering scientific expertise across complex delivery formats including oral solids, complex injectables and ophthalmics
- Extends operational footprint to include rigorous bioequivalence and stability studies
- Enables comprehensive regulatory filings tailored for diverse global markets
- Expands global customer base in generic pharmaceutical segment
- Scales up value proposition for global CDMO customers through expanded service platform covering pre-formulation studies, prototype development, process optimization, scale-up, clinical supplies and commercial manufacturing
- Complements with analytical development, methods validation, stability programmes and regulatory submission support
- Strategic focus on leveraging IQGenX's platform alongside Alivus's world-class API portfolio, primarily in Oncology
- Aims to curate high-impact basket of differentiated, niche assets for strategic out-licensing across multiple geographies
Transaction Timeline and Conditions
- Subject to customary closing condition precedents
- Expected to close by end of current calendar year (2026)
Company Background
Alivus Life Sciences Limited (BSE: 543322, NSE: ALIVUS) is a leading developer and manufacturer of select, high-value, non-commoditized APIs in chronic therapeutic areas including cardiovascular disease, central nervous system disease, pain management and diabetes. The company has a diversified portfolio of 181 molecules and supplies to customers in India, Europe, North America, Latin America, Japan, and Rest of the World. It operates four manufacturing facilities in Ankleshwar, Dahej, Mohol and Kurkumbh with total installed capacity of 1424 KL, regularly inspected by global regulators including USFDA, PMDA (Japan) and EDQM (Europe).